User login
Key clinical point: Ubrogepant as an acute treatment for episodic migraine in adults is associated with an increased rate of achieving freedom from pain and absence of the most bothersome symptoms at 2 hours post-dose.
Major finding: At 2 hours post-dose, ubrogepant vs placebo use was associated with a significantly higher percentage of patients with pain freedom (20.80% vs 12.60%; relative risk [RR], 1.65) and absence of the most bothersome migraine-associated symptoms (37.34% vs 27.58%; RR, 1.35) (P less than .001 for both). No significant difference was observed in treatment-related adverse events within 48 hours or 30 days between the two groups.
Study details: Meta-analysis of 3 randomized clinical trials including 3,326 participants.
Disclosures: This study was supported by the Suzhou Health Talents Training Project. The authors declared no conflicts of interest.
Citation: Yang Y et al. CNS Drugs. 2020 Mar 19. doi: 10.1007/s40263-020-00715-7.
Key clinical point: Ubrogepant as an acute treatment for episodic migraine in adults is associated with an increased rate of achieving freedom from pain and absence of the most bothersome symptoms at 2 hours post-dose.
Major finding: At 2 hours post-dose, ubrogepant vs placebo use was associated with a significantly higher percentage of patients with pain freedom (20.80% vs 12.60%; relative risk [RR], 1.65) and absence of the most bothersome migraine-associated symptoms (37.34% vs 27.58%; RR, 1.35) (P less than .001 for both). No significant difference was observed in treatment-related adverse events within 48 hours or 30 days between the two groups.
Study details: Meta-analysis of 3 randomized clinical trials including 3,326 participants.
Disclosures: This study was supported by the Suzhou Health Talents Training Project. The authors declared no conflicts of interest.
Citation: Yang Y et al. CNS Drugs. 2020 Mar 19. doi: 10.1007/s40263-020-00715-7.
Key clinical point: Ubrogepant as an acute treatment for episodic migraine in adults is associated with an increased rate of achieving freedom from pain and absence of the most bothersome symptoms at 2 hours post-dose.
Major finding: At 2 hours post-dose, ubrogepant vs placebo use was associated with a significantly higher percentage of patients with pain freedom (20.80% vs 12.60%; relative risk [RR], 1.65) and absence of the most bothersome migraine-associated symptoms (37.34% vs 27.58%; RR, 1.35) (P less than .001 for both). No significant difference was observed in treatment-related adverse events within 48 hours or 30 days between the two groups.
Study details: Meta-analysis of 3 randomized clinical trials including 3,326 participants.
Disclosures: This study was supported by the Suzhou Health Talents Training Project. The authors declared no conflicts of interest.
Citation: Yang Y et al. CNS Drugs. 2020 Mar 19. doi: 10.1007/s40263-020-00715-7.